CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Taipei, Taiwan and 113 other locations
in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...
Phase 3
Taipei, Taiwan and 117 other locations
cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian...
Phase 3
Taipei, Taiwan and 148 other locations
following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...
Phase 3
Taipei, Taiwan and 237 other locations
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer...
Phase 2, Phase 3
Taipei, Taiwan and 80 other locations
and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...
Phase 3
Taipei, Taiwan and 226 other locations
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer...
Phase 1, Phase 2
Taipei, Taiwan and 48 other locations
2-) breast cancer (hormone receptor-positive \[HR+\]/HER2-breast cancer \[BC\]), head and neck squamous-cell-carcinoma (HNSCC), Pla ...
Phase 1
Taipei City, Taipei, Taiwan and 52 other locations
to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A s...
Phase 1
Taipei City, Taipei, Taiwan and 44 other locations
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors th...
Phase 2
Taipei City, Taiwan and 122 other locations
Clinical trials
Research sites
Resources
Legal